

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MPM BIOVENTURES III LLC</u> (Last) (First) (Middle) <u>C/O MPM ASSET MANAGEMENT</u> <u>200 CLARENDON ST., 54TH FLOOR</u> (Street) <u>BOSTON MA 02116</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/03/2007</u>	3. Issuer Name and Ticker or Trading Symbol <u>HEALTHCARE ACQUISITION CORP [HAQ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) _____ <u>See explanation below</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person _____ <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>125,000</u>	<u>I</u>	<u>See Footnote⁽¹⁾</u>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person*
MPM BIOVENTURES III LLC
 (Last) (First) (Middle)
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR
 (Street)
BOSTON MA 02116
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MPM BIOVENTURES III PARALLEL FUND, LP
 (Last) (First) (Middle)
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR
 (Street)
BOSTON MA 02116
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MPM BIOVENTURES III GMBH & CO. Beteiligungs KG
 (Last) (First) (Middle)
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR
 (Street)
BOSTON MA 02116
 (City) (State) (Zip)

(Street)
BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[MPM BIOVENTURES III LP](#)

(Last) (First) (Middle)
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[MPM BIOVENTURES III GP LP](#)

(Last) (First) (Middle)
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[MPM BIOVENTURES III QP LP](#)

(Last) (First) (Middle)
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[MPM Asset Management Investors 2004 BVIII LLC](#)

(Last) (First) (Middle)
C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)

Explanation of Responses:

1. The shares are held as follows: 103,672 by MPM BioVentures III-QP, L.P. ("BV III QP"), 6,971 by MPM BioVentures III, L.P. ("BV III"), 2,465 by MPM Asset Management Investors 2004 BVIII LLC ("AM 2004"), 3,131 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 8,761 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadick, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2004. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Remarks:

The Reporting Person is a member of a Section 13(d) group owning more than 10% of the Issuer's common stock. See Form 3 for Luke Evnin for additional members of this joint filing.

[/s/ Luke Evnin, Series A](#)
[Member of MPM BioVentures III LLC](#) 08/07/2007
[/s/ Luke Evnin, Series A](#)
[Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP](#) 08/07/2007
[the general partner of MPM BioVentures III Parallel Fund, LP](#)

<u>/s/ Luke Evnin, Series A</u>	<u>08/07/2007</u>
<u>Member of MPM BioVentures</u>	
<u>III LLC, the general partner of</u>	
<u>MPM BioVentures III GP, LP,</u>	
<u>in its capacity as the Managing</u>	
<u>Limited Partner of MPM</u>	
<u>BioVentures III GmbH & Co.</u>	
<u>Beteiligungs KG</u>	
<u>/s/ Luke Evnin, Series A</u>	
<u>Member of MPM BioVentures</u>	
<u>III LLC, the general partner of</u>	<u>08/07/2007</u>
<u>MPM BioVentures III GP, LP,</u>	
<u>the general partner of MPM</u>	
<u>BioVentures III, LP</u>	
<u>/s/ Luke Evnin, Series A</u>	
<u>Member of MPM BioVentures</u>	<u>08/07/2007</u>
<u>III LLC, the general partner of</u>	
<u>MPM BioVentures III GP, LP</u>	
<u>/s/ Luke Evnin, Series A</u>	
<u>Member of MPM BioVentures</u>	
<u>III LLC, the general partner of</u>	<u>08/07/2007</u>
<u>MPM BioVentures III GP, LP,</u>	
<u>the general partner of MPM</u>	
<u>BioVentures III QP, LP</u>	
<u>/s/ Luke Evnin, manager of</u>	
<u>MPM Asset Management</u>	<u>08/07/2007</u>
<u>Investors 2004 BVIII LLC</u>	

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.